
Photo: Capsules and pills (generic illustration — not the actual Indian cancer drugs). Credit: Abinoam Jr., CC BY-SA 3.0, via Wikimedia Commons.
Cancer drug prices in India are set to fall by up to 70 percent after the country's drug-price regulator capped the profit margin on 137 anti-cancer medicines, in the biggest intervention in cancer care since 2019. The National Pharmaceutical Pricing Authority (NPPA) issued an order fixing the trade margin at 30 percent of the maximum retail price for 137 non-scheduled anti-cancer drugs, in a gazette notification dated October 17, 2026, with the revised prices taking effect from November 9. The move is expected to benefit cancer patients across the country, particularly the more than 70 percent who rely on private treatment, where drug costs are the largest part of the bill. Pharmaceutical companies have already filed revised prices for 1,136 formulations across 120 drugs, and the steepest cuts run to more than 96 percent on some medicines. The government says the intervention will make life-saving treatment affordable for lakhs of families; the question now is whether the lower prices reach patients at the pharmacy counter.
What the Order Does
The NPPA's order caps the trade margin — the difference between the price at which a drug is sold to distributors and the price printed on the pack — at 30 percent of the maximum retail price (MRP) for 137 anti-cancer drugs. It is the first intervention of its kind since 2019, when the regulator capped margins on 42 anti-cancer drugs, and it is substantially larger: the list includes 137 medicines covering immunotherapy for more than 20 types of cancer, along with denosumab, pegfilgrastim and bevacizumab, and patented drugs are covered too. The legal basis for the order is Paragraph 19 of the Drugs (Prices Control) Order, 2013, which allows the regulator to act in the public interest. The drugs were chosen from a list prepared by an expert committee of oncologists under the Directorate General of Health Services, and the order was issued as a gazette notification on October 17, 2026, with the revised prices taking effect from November 9, 2026. As of November 4, 70 companies had filed revised prices for 1,136 stock-keeping units of 120 drugs, with the cuts running mostly between 20 and 70 percent, and the steepest single cut reaching 96.45 percent. Imported medicines are covered too: the margin cap applies to the MRP printed on imported packs, including drugs such as pembrolizumab, durvalumab and osimertinib.
How Much Patients Could Save
The government expects the move to save patients a substantial amount, although the published estimates differ. Moneycontrol reported an earlier official estimate of Rs25 billion a year, equivalent to about $263 million, while the NPPA's own calculation, reported by Behind Talkies, puts the saving at Rs3,357.49 crore — roughly Rs33.6 billion — based on sales volumes between April 2025 and March 2026. Medindia, meanwhile, reported an estimate of Rs2,500 crore a year. The three figures come from different methods and different time periods, so they are not directly comparable, but all three point to savings in the tens of billions of rupees. The scale of the problem is large: India recorded about 1.46 million new cancer cases in 2025, with the number expected to rise to 1.57 million by 2030, according to official data, and drug costs are the biggest barrier to treatment for most families. There is one catch. The order applies to new batches, and old stock already on pharmacy shelves will continue to sell at the old price until it is cleared. Patients are advised to check the revised prices on the NPPA website or the government's Pharma Sahi Daam app before buying, and to ask their chemist for the new batch. The government says the revised prices are already being enforced, and the regulator has the power to act against companies that fail to comply.
Why This Matters Beyond India
India's intervention matters beyond its own borders because it is one of the world's largest suppliers of generic medicines, and its pricing decisions set a benchmark for other developing countries. The move comes as cancer rates rise across South Asia, including in Pakistan, where patients often depend on imported drugs and face prices far above Indian levels. It also shows what a regulator can do with a single legal tool: the margin cap does not require new legislation, only an order under an existing law, and it leaves manufacturers with a guaranteed 30 percent margin rather than imposing a price ceiling. Whether the model travels will depend on whether the cuts actually reach patients. Past price controls in India have sometimes been undermined by companies withdrawing products or by pharmacies selling old stock, and the regulator will need to monitor compliance closely. For now, though, the order is a rare piece of good news in a disease that bankrupts families. If the savings materialise at the scale the NPPA calculates, it will be the largest single reduction in the cost of cancer treatment in India's history.
Related reading on The Global Thinker: see also our reports on petrol cut to Rs338 in Pakistan and tankers still burning in the Strait of Hormuz. More on this topic: Business News
Frequently Asked Questions
Which cancer drugs have become cheaper in India?
The NPPA capped the trade margin at 30 percent of the MRP for 137 non-scheduled anti-cancer drugs, including immunotherapy for more than 20 cancers, denosumab, pegfilgrastim, bevacizumab and patented drugs such as pembrolizumab, durvalumab and osimertinib.
How much will cancer drug prices fall?
Most prices fall by 20 to 70 percent, with the steepest single cut reaching 96.45 percent. The revised prices took effect on November 9, 2026.
How much will patients save?
Estimates differ: the NPPA calculates savings of Rs3,357.49 crore a year, Moneycontrol reported an earlier estimate of Rs25 billion, and Medindia reported Rs2,500 crore. All three point to savings in the tens of billions of rupees.
Sources
- Press Information Bureau (Government of India), "National Pharmaceutical Pricing Authority caps trade margin at 30% of MRP on 137 non-scheduled anti-cancer drugs" — https://pib.gov.in/PressReleaseIframePage.aspx?PRID=2183298
- Moneycontrol, "NPPA caps margins on 137 anti-cancer drugs; prices may fall up to 70%" — https://www.moneycontrol.com/news/india/nppa-caps-margins-on-137-anti-cancer-drugs-prices-may-fall-up-to-70-13582068.html
- News18, "Cancer Drug Prices Slashed By Up To 70% In India" — https://www.news18.com/business/cancer-drug-prices-slashed-by-up-to-70-in-india-137-medicines-nppa-10420027.html
- Moneylife, "NPPA Caps Trade Margin on 137 Anti-Cancer Drugs at 30% of MRP; Prices to Drop Up to 70%" — https://www.moneylife.in/article/nppa-caps-trade-margin-on-137-anti-cancer-drugs-at-30-of-mrp-prices-to-drop-up-to-70/79928.html
- Organiser, "NPPA caps margins on 137 anti-cancer drugs; MRPs to fall by up to 70%" — https://organiser.org/2026/10/24/344823/bharat/nppa-caps-margins-on-137-anti-cancer-drugs-mrps-to-fall-by-up-to-70/
- Medindia, "NPPA caps trade margin for 137 cancer drugs at 30%: Prices may fall up to 70%" — https://www.medindia.net/news/healthinfocus/nppa-caps-trade-margin-for-137-cancer-drugs-at-30-prices-may-fall-up-to-70-222116-1.htm
Comments
Post a Comment